Get started
Author

Anne E. O’Shea

Observed names: A. O'Shea, A. O’Shea, Anne E O'Shea, Anne E O’Shea, Anne E. O'Shea, Anne O'Shea, Anne O’Shea
ORCID: 0000-0003-0785-8563
Observed ORCID: 0000-0003-0785-8563
OpenAlex ID: A5074470440
Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention
2022 · Anne E. O'Shea, Franklin A. Valdera, et al. · Clinical Immunology · 38
AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence
2020 · Patrick M. McCarthy, G. Travis Clifton, et al. · Expert Opinion on Investigational Drugs · 31
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
2023 · Elizabeth Lee Carpenter, Spencer Van Decar, et al. · Journal for ImmunoTherapy of Cancer · 24
PDF
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
2023 · Anne E. O'Shea, Guy T. Clifton, et al. · Cancer Prevention Research · 24
PDF
Rates, Predictors, and Outcomes of Portal Lymphadenectomy for Resectable Gallbladder Cancer
2021 · Phillip M. Kemp Bohan, Anne E. O’Shea, et al. · Annals of Surgical Oncology · 23
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials
2023 · Patrick M. McCarthy, Franklin A. Valdera, et al. · Frontiers in Immunology · 18
PDF
Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma
2021 · Patrick M McCarthy, Matthew J Rendo, et al. · OncoTargets and Therapy · 15
PDF
Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression
2021 · Phillip M. Kemp Bohan, Robert C. Chick, et al. · Cancer Prevention Research · 15
PDF
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial
2022 · Alexandra M. Adams, Elizabeth L. Carpenter, et al. · Cancer Immunology Immunotherapy · 14
PDF
Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival
2022 · Anne E. O’Shea, Phillip M. Kemp Bohan, et al. · Annals of Surgical Oncology · 11
Lymph node sampling in resectable hepatocellular carcinoma: national practice patterns and predictors of positive lymph nodes
2020 · Phillip M. Kemp Bohan, Anne E. O'Shea, et al. · Surgical Oncology · 10
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
2024 · Spencer G. Van Decar, Elizabeth L. Carpenter, et al. · Cancer Treatment and Research Communications · 5
Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters
2023 · Franklin A. Valdera, Anne E. O'Shea, et al. · Journal of Surgical Oncology · 4
Analysis of Concomitant and Isolated Venous Injury in Military Lower Extremity Trauma
2022 · Anne E. O'Shea, Christina Lee, et al. · Annals of Vascular Surgery · 4
Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer
2021 · Anne E. O’Shea, Guy T. Clifton, et al. · Oncotarget · 4
PDF
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
2021 · Alexandra M. Adams, Robert C. Chick, et al. · Melanoma Research · 4
Thymic adenocarcinoma presenting as an incidental mediastinal mass
2022 · Anne E. O’Shea, Alexander P. Nissen, et al. · Journal of Cardiothoracic Surgery · 3
PDF
The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy
2024 · Elizabeth L. Carpenter, Spencer G. Van Decar, et al. · Journal of Surgical Oncology · 2
300 Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis
2020 · Lexy Adams, Robert Chick, et al. · Regular and Young Investigator Award Abstracts · 2
PDF
310 The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma
2020 · Anne O’Shea, Robert Chick, et al. · Regular and Young Investigator Award Abstracts · 2
PDF
ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancreatic Adenocarcinoma
2022 · Anne E. O’Shea, Elizabeth L. Carpenter, et al. · Annals of Surgical Oncology · 1
Analysis Of Concomitant And Isolated Venous Injury In Military Lower Extremity Trauma
2022 · Anne E O'Shea, Matthew Burgess, et al. · Annals of Vascular Surgery · 1
542 Randomized trial of tumor lysate particle only vaccine vs. tumor lysate particle-loaded, dendritic cell vaccine to prevent recurrence of resected stage III/IV melanoma: 36-month analysis
2021 · Elizabth Carpenter, Lexy Adams, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Abstract PD11-09: Vadis trial: Phase II trial of nelipepimut-s peptide vaccine in women with DCIS of the breast
2021 · Anne E O'Shea, Guy T Clifton, et al. · Cancer Research · 1
431 Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma
2020 · Patrick McCarthy, Lexy Adams, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Works count: 93
Citation count: 258
H-index: 10
I10-index: 11
Year
Topic
Type